Journal
PLOS ONE
Volume 16, Issue 3, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0248348
Keywords
-
Categories
Funding
- US Food and Drug Administration
Ask authors/readers for more resources
Pseudoviruses are valuable surrogates for highly pathogenic viruses due to their safety, stability, and scalability, with diverse platforms offering varied advantages and limitations. This study optimized and characterized an HIV-based lentiviral pseudovirus assay for screening neutralizing antibodies for SARS-CoV-2, showing consistent neutralization titers across different input ranges and high correlation with other assays' results. Overall, the lentiviral assay is simple, scalable, and suitable for various SARS-CoV-2 entry and neutralization screening assays.
Pseudoviruses are useful surrogates for highly pathogenic viruses because of their safety, genetic stability, and scalability for screening assays. Many different pseudovirus platforms exist, each with different advantages and limitations. Here we report our efforts to optimize and characterize an HIV-based lentiviral pseudovirus assay for screening neutralizing antibodies for SARS-CoV-2 using a stable 293T cell line expressing human angiotensin converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). We assessed different target cells, established conditions that generate readouts over at least a two-log range, and confirmed consistent neutralization titers over a range of pseudovirus input. Using reference sera and plasma panels, we evaluated assay precision and showed that our neutralization titers correlate well with results reported in other assays. Overall, our lentiviral assay is relatively simple, scalable, and suitable for a variety of SARS-CoV-2 entry and neutralization screening assays.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available